Reclinic
Dr. Khanin
Home › Health articles › GLP-1 weight-loss medicines and the knee
Health articles · Knee and hip
GLP-1 weight-loss medicines,
knee osteoarthritis and joint replacement
Body weight affects knee osteoarthritis both during non-surgical treatment and when a joint replacement is needed. Losing about 10% of body weight clearly eases knee pain [1], while people who are very overweight have a higher chance of infection after joint replacement [2]. GLP-1 injections, such as semaglutide and tirzepatide, are prescription-only medicines that led to large weight loss in studies [3]. This article brings together the research on these medicines and knee osteoarthritis, the side effects to know about, and how to prepare if you use them and are planning surgery. By Assoc. Prof. Khanin, orthopedic surgeon, Reclinic Hat Yai.

Written and reviewed by Assoc. Prof. Khanin Iamthanaporn, MD
Orthopedic surgeon (Thai Medical Council license no. 35052) · Last reviewed November 2026 · About 9 min read
How is body weight linked to knee pain?
Many people already know that losing weight helps the knee, but it is hard to do, especially when knee pain limits exercise, and that is nobody's fault. With every step, the knee carries a force several times your body weight; when weight goes down, the force on the knee goes down too [6]
What research has found
✓ International knee osteoarthritis guidelines recommend weight loss for people who are overweight, as a main treatment alongside exercise [7]
✓ Losing more than about 5% of body weight improves knee function [8]
✓ The more weight lost, the better the symptoms; people who lost 10–20% had clearly less pain than those who lost less than 10% [1]
✓ Diet together with exercise eases pain more than exercise alone [6]
✓ Diet and exercise remain the basis for everyone; medicines are only an extra help for some people
So weight is a factor that helps non-surgical treatment of knee osteoarthritis, such as muscle exercises, medicines or injections, work better. For hip osteoarthritis, weight matters less than for the knee, and there are no studies of these medicines in the hip directly yet.
How does body weight affect joint replacement?
People who are very overweight can still have a joint replacement, and most benefit clearly, but the chance of some complications is higher. Knowing this helps you prepare.
Infection after surgery
A study of more than 9,000 patients found a similar chance of infection when BMI was below 35, but about 2 times higher at 35–39.9 and about 4 times higher at 40 or more [2]
Diabetes with severe overweight
People with both have a higher chance of infection, so controlling blood sugar before surgery matters too [9]
Revision surgery later on
Pooled studies of knee replacement found that people who are overweight have a slightly higher chance of needing revision surgery [10]
Weight is not the only criterion
A study of more than 27,000 patients found that if a BMI of 40 were used as a cut-off for refusing surgery, about 14 patients who could have had surgery without complications would be turned away for every 1 complication prevented [11]
Assoc. Prof. Khanin does not use weight as a cut-off for deciding whether someone can have surgery. He considers it together with other health conditions, symptoms and how ready the patient is. Weight care before surgery helps lower the risk; it is not a condition you have to pass.
What are GLP-1 medicines?
How the medicines work
They copy a hormone the gut releases after eating, so you feel full sooner and for longer and the stomach empties more slowly; you eat less without feeling very hungry. They were first used for diabetes and later, at different doses, for weight care. They are injected under the skin once a week, starting at a low dose that is raised about every 4 weeks.
How do semaglutide and tirzepatide differ?
Semaglutide acts on the GLP-1 receptor, while tirzepatide acts on both the GLP-1 and GIP receptors. A randomized trial comparing the two directly found an average weight loss at 72 weeks of about 20% with tirzepatide and about 14% with semaglutide [3]
Since 15 September 2026, these injections have been specially controlled drugs in Thailand: they need a doctor's prescription and must be dispensed by a pharmacist. Do not buy them online or from unknown sources, because they may be fake or stored incorrectly.
What has research in knee osteoarthritis found?
The key studies on these medicines and knee osteoarthritis can be summed up as follows.
Semaglutide in people with severe overweight and knee osteoarthritis
A randomized trial of 407 people followed for 68 weeks (average BMI about 40) found weight loss of about 14% compared with 3% on placebo. Knee pain scores fell clearly more than with placebo, and walking and daily activities improved [12]
The placebo group also improved
In the same trial, people who had placebo plus advice on diet and exercise also had a fair drop in pain, showing that changing habits is helpful in itself [12]
Tirzepatide
Led to large weight loss in randomized trials [13], but so far no published randomized trial has looked at knee osteoarthritis symptoms directly, and a study is under way on whether it reduces the need for knee replacement.
The medicines do not repair cartilage
The effect on pain comes mostly from the weight lost. There is no evidence that the medicines bring back cartilage that has worn away.
The effect lasts while the medicine is continued
One year after stopping semaglutide, about 2 in 3 of the weight lost came back [4]. In a tirzepatide trial, people switched to placebo regained about 14% within about a year, while those who stayed on the medicine kept losing weight [14]
Knee osteoarthritis studies were done in people with severe overweight; the effect in people who are only slightly overweight may be smaller.
Who might they suit, and who should be careful?
Whether these medicines are used depends on weight, other health conditions, current medicines and the patient's own goals. The doctor always assesses each person individually, and they are always used together with diet and exercise.
May suit
People who are clearly overweight, or overweight with a related condition such as diabetes, high blood pressure, high cholesterol or knee osteoarthritis, who have tried diet and exercise but lost little weight. For Asian people, health risks start to rise at a lower BMI than for Western people [15]
Should not be used
People who themselves or whose family have had medullary thyroid cancer or MEN 2, and people who are pregnant, breastfeeding or planning a pregnancy
Use with care and tell your doctor
People who have had pancreatitis, gallstones, kidney disease or diabetic eye disease, or who also use insulin or some other blood-sugar medicines
People taking birth control pills
Tirzepatide may make birth control pills work less well when starting the medicine and when the dose is raised; talk to your doctor about using another method of birth control as well.
GLP-1 medicines with lifestyle changes
Diet and exercise
Weight lost in studies
Effect on knee pain
Clearly less (semaglutide) [12]
Less [6]
Common side effects
Nausea, vomiting, diarrhea, constipation [16]
Aches at first
After stopping
Depends on keeping up the habits
Can they be combined?
Should always be combined
The basis for everyone
GLP-1 medicines with lifestyle changes
Side effects to know about
Most side effects are mild and happen early in treatment, but there are some you should know about.
Nausea, vomiting, diarrhea, constipation
Common, especially when starting the medicine and when the dose is raised; usually mild and gradually better. In studies, about 4–8 in 100 users stopped the medicine because of side effects [16][13][3]
Muscle lost along with fat
Most of the weight lost is fat, but about 1 in 4 is non-fat mass, which includes muscle [17]. So people with knee osteoarthritis or who are about to have surgery should eat enough protein and keep doing muscle exercises.
Gallstones and pancreatitis
Gallstones are slightly more common when weight is lost quickly, while pancreatitis is rare [16]. If you have severe stomach pain spreading to the back, or pain in the upper right abdomen with a fever, see a doctor right away.
Sudden blurred vision
A very rare loss of blood supply to the optic nerve has been reported. If your vision suddenly blurs or you cannot see, see a doctor quickly.
Dehydration from vomiting or diarrhea
This can reduce kidney function. Drink enough water, and talk to your doctor if vomiting or diarrhea is severe.
⚠ See a doctor right away if
you have severe stomach pain that does not go away, vomit so much that you cannot eat or drink, have yellow skin or eyes, sudden blurred vision, or an allergic reaction such as a swollen face or difficulty breathing
Using these medicines and planning a knee or hip replacement
What research has found Pooled data from more than 96,000 patients found that people who used these medicines before knee or hip replacement had fewer complications and fewer hospital readmissions within 90 days than those who did not [18]. But all the data came from looking back at records, so its reliability is low. Another review found slightly more fractures around the implant in the first year [19], and at 2 years there was no clear benefit [20]. So it cannot yet be concluded that the medicines improve surgical results, and they may not bring weight down to the target in everyone [21]
Before the day of surgery These medicines make the stomach empty more slowly, so food may remain in the stomach even after fasting for the usual time, which raises the risk of breathing in stomach contents during anesthesia or sedation. Joint guidance from anesthesia and gastroenterology societies in 2024 and UK guidance in 2025 recommend that most patients can continue the medicine, with each person's risk assessed. People at higher risk, such as those in the dose-raising phase, on a high dose, or still having nausea, vomiting or bloating, may need clear liquids only for 24 hours before surgery, or the doctor may ask them to stop the medicine beforehand [5][22]
Advice can differ between hospitals, so follow what your doctor and anesthesiologist tell you, and do not stop or change the medicine yourself.
If you use these medicines and have a joint replacement booked, what should you do?
1
Tell your doctor when surgery is booked
Give the medicine name, dose and date of your last injection to both the surgeon and the anesthesiologist
2
Do not raise the dose close to surgery
Nausea usually happens when the dose is raised, so surgery should take place once you have been on the same dose and symptoms are stable [5]
3
Follow the advice on food before surgery
Some people may need clear liquids for 24 hours before surgery, or to stop the medicine beforehand as the doctor advises [5][22]
4
Day of surgery
Tell the anesthesiologist again, especially if you still have nausea, vomiting or bloating
5
After surgery
Restart the medicine once you are eating normally without nausea or vomiting. If you stopped it for several weeks, the doctor may restart it at a low dose. Meanwhile, eat enough protein and practice walking as planned
6
Long-term weight care
Looking after your weight after surgery helps protect the new joint and your other joints
Read the full preparation guide on Preparing for joint replacement →
Using the medicines safely and well
Things to do
✓ Use the medicine as prescribed, and see your doctor as scheduled to follow weight and side effects
✓ Do not buy the medicines online or from unknown sources
✓ Eat enough protein at every meal and drink enough water
✓ Exercise your thigh and hip muscles regularly, with low-impact exercise such as cycling or swimming
✓ Eat slowly, in small meals, and stop when full, to reduce nausea
✓ Always tell the doctor before surgery, endoscopy or anesthesia
✓ Plan with your doctor from the start how you will look after your weight when you stop the medicine
Read more
Preparing for joint replacement
Medicines to tell your doctor about, exercises and your hospital stay
Frequently asked questions
Book a visit with Dr. Khanin
Do you have knee pain and worry about your weight, or are you planning a joint replacement? Come in so we can plan your knee care together. You can see Assoc. Prof. Khanin on Tuesday–Thursday 5:00–7:00 PM and Saturday–Sunday 9:00 AM–12:00 PM.
Call 062-498-3913 · LINE @khaninclinic · Facebook khaninortho
References
Messier SP, et al. Intentional weight loss in overweight and obese patients with knee osteoarthritis: is more better? Arthritis Care Res 2018;70:1569–1575.
Lübbeke A, et al. Body mass and weight thresholds for increased prosthetic joint infection rates after primary total joint arthroplasty. Acta Orthop 2016;87:132–138.
Aronne LJ, et al. Tirzepatide as compared with semaglutide for the treatment of obesity. N Engl J Med 2025;393:26–36.
Wilding JPH, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: the STEP 1 trial extension. Diabetes Obes Metab 2022;24:1553–1564.
Kindel TL, et al. Multisociety clinical practice guidance for the safe use of glucagon-like peptide-1 receptor agonists in the perioperative period. Surg Obes Relat Dis 2024;20:1183–1186.
Messier SP, et al. Effects of intensive diet and exercise on knee joint loads, inflammation, and clinical outcomes among overweight and obese adults with knee osteoarthritis: the IDEA randomized clinical trial. JAMA 2013;310:1263–1273.
Kolasinski SL, et al. 2019 American College of Rheumatology/Arthritis Foundation guideline for the management of osteoarthritis of the hand, hip, and knee. Arthritis Rheumatol 2020;72:220–233.
Christensen R, et al. Effect of weight reduction in obese patients diagnosed with knee osteoarthritis: a systematic review and meta-analysis. Ann Rheum Dis 2007;66:433–439.
Jämsen E, et al. Obesity, diabetes, and preoperative hyperglycemia as predictors of periprosthetic joint infection: a single-center analysis of 7181 primary hip and knee replacements for osteoarthritis. J Bone Joint Surg Am 2012;94:e101.
Kerkhoffs GM, et al. The influence of obesity on the complication rate and outcome of total knee arthroplasty: a meta-analysis and systematic literature review. J Bone Joint Surg Am 2012;94:1839–1844.
Giori NJ, et al. Risk reduction compared with access to care: quantifying the trade-off of enforcing a body mass index eligibility criterion for joint replacement. J Bone Joint Surg Am 2018;100:539–545.
Bliddal H, et al. Once-weekly semaglutide in persons with obesity and knee osteoarthritis. N Engl J Med 2024;391:1573–1583.
Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity. N Engl J Med 2022;387:205–216.
Aronne LJ, et al. Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity: the SURMOUNT-4 randomized clinical trial. JAMA 2024;331:38–48.
WHO Expert Consultation. Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies. Lancet 2004;363:157–163.
Wilding JPH, et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med 2021;384:989–1002.
Look M, et al. Body composition changes during weight reduction with tirzepatide in the SURMOUNT-1 study of adults with obesity or overweight. Diabetes Obes Metab 2025;27:2720–2729.
Rudran B, et al. Glucagon-like peptide-1 receptor agonists are associated with improved 90-day outcomes after total hip and knee arthroplasty: a systematic review and meta-analysis. Bone Joint J 2026;108-B:986–994.
Wajda B, et al. Glucagon-like peptide-1 receptor agonists in hip and knee arthroplasty: a comprehensive systematic review and meta-analysis of perioperative and postoperative outcomes. Arthroplast Today 2026;39:102043.
Leggieri F, et al. No mid-term benefits of glucagon-like peptide-1 (GLP-1) receptor agonists following total joint arthroplasty: a systematic review. J Bone Joint Surg Am 2026;108:639–648.
Chan PYW, et al. Glucagon-like peptide-1 agonists: what the orthopaedic surgeon needs to know. JBJS Rev 2024;12(1).
El-Boghdadly K, et al. Elective peri-operative management of adults taking glucagon-like peptide-1 receptor agonists, glucose-dependent insulinotropic peptide agonists and sodium-glucose cotransporter-2 inhibitors: a multidisciplinary consensus statement. Anaesthesia 2025;80:412–424.
The information in this article is to help with early decisions. It does not replace an examination and advice from a doctor. These medicines must be used under a doctor's care.